A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies (Lymphoma)
Study of STK-009 in Combination with SYNCAR-001 in Patients with Lymphoma or Leukemia
Sponsor: Synthekine, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU3113
U.S. Govt. ID: NCT05665062
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at various times, whether your immune system becomes activated, whether your body produces antibodies (proteins produced by your immune system) against SYNCAR-001 and/or STK-009, and the effects of SYNCAR-001 + STK-009 on your cancer.
This study is closed
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you able to give informed consent? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator